



## APPLICATION

### DIRECTIONS

The Principal Investigator (PI) responsible for overseeing the project and controlling the laboratory and personnel who will receive, use and process the requested specimens should complete this application. Any transfer of samples, aliquots, derivatives or associated clinical data to collaborating personnel or laboratories that are not under the direct supervision of the indicated PI requires the following:

- A written justification of the need to transfer the materials and benefit to the applicant's research.
- Copies of the AGREEMENT FOR USE OF TISSUE and DATA USE AGREEMENT signed by the collaborator.
- Documentation of the collaborator's IRB approval or exemption unless the collaborator is covered under the IRB approval granted for the project proposed in this application.


The CHTN does not supply samples to specimen banks whose purpose is distribution to third-party researchers; those researchers should be encouraged to apply to the CHTN directly.

The information in these forms is necessary in order to document correctly your request for tissue and other services and to ensure that the CHTN operates within the guidelines of the National Cancer Institute. When submitting a written request for services:

1. Please print neatly or type.
2. If requesting specimens from more than one specific anatomic site or disease, please complete separate copies of the Request Information Form (biospecimen, donor and preparation details) as necessary. Please be specific about your requirements, including those for storing and handling tissue samples from the time the specimens are collected until they are delivered to your lab (i.e. transport media, refrigeration status, etc.).
3. Patient identity is confidential. Samples and accompanying clinical data will be identified by a code, which will not be released under any circumstances.
4. The PI is responsible for remission of processing fees to the originating CHTN division for each specimen provided, including fees for any additional services performed and any shipping costs not directly billed to the applicant's courier account. Please refer to our website, [www.chtn.org](http://www.chtn.org), for the current fee table.
5. PIs must obtain human subjects review from their institution in order to receive specimens from the CHTN. Full or expedited approval or an exemption for your project can be obtained from your Institutional Review Board (IRB) (Human Use Committee). **A copy of the Human Subjects approval or review documentation should be returned with this form.** Documentation of annual review of non-exempt protocols by the PI's institution must be forwarded to the CHTN in order to maintain eligibility to receive tissue. This is not necessary for exempt protocols. If your institution does not have internal review, contact your divisional coordinator. **NOTE:** Tissue Microarrays are fully anonymized and do not require documentation of IRB approval or exemption.
6. Please provide a signed copy of the Agreement for Use of Tissue and Data Use Agreement (Agreements included below). **The language in both agreements is NOT to be altered.**
7. The CHTN is divided into five geographic regions as identified on the map below. PIs should submit their application to the appropriate division based on his/her geographic location. PIs from any geographic area REQUESTING PEDIATRIC SPECIMENS ONLY should forward their completed application directly to the Pediatric Division at The Research Institute at Nationwide Children's Hospital.

8. For additional information, please direct any questions to the division serving your state/geographic region.

**GEOGRAPHIC REGIONS/DIVISIONS & DIVISIONAL CONTACTS**



**PIs from any geographic area REQUESTING PEDIATRIC SPECIMENS ONLY should forward their completed application directly to the Pediatric Division at the Research Institute at Nationwide Children’s Hospital.**

<p><b>Eastern Division</b> Tel: 215-662-4570 Fax: 215-614-0251</p> <p>Division Coordinator: Dee McGarvey, <a href="mailto:dfitzsim@mail.med.upenn.edu">dfitzsim@mail.med.upenn.edu</a> PI: Dr. Virginia LiVolsi</p> <p><i>Mailing Address:</i> 3400 Spruce St. 566 Dulles Hospital of the University of Pennsylvania Philadelphia, PA 19104</p>	<p><b>Mid-Atlantic Division</b> Tel: 434-924-9879 Fax: 434-924-9438</p> <p>Division Coordinator: Craig Rumpel, <a href="mailto:chtn-midatl@hscmail.mcc.virginia.edu">chtn-midatl@hscmail.mcc.virginia.edu</a> PI: Dr. Christopher Moskaluk</p> <p><i>Mailing Address:</i> CHTN, Mid-Atlantic Division University of Virginia Dept. of Pathology Box 800904 Charlottesville, VA 22908</p>	<p><b>Midwestern Division</b> Tel: 614-293-5493 Fax: 614-293-7013</p> <p>Division Coordinator: Randy Mandt, <a href="mailto:randy.mandt@osumc.edu">randy.mandt@osumc.edu</a> PI: Dr. Leona Ayers</p> <p><i>Mailing Address:</i> CHTN Midwestern Division Innovation Centre 2001 Polaris Parkway Columbus, OH 43240</p>
<p><b>Pediatric Division</b> Tel: 614-355-3547 Fax: 614-722-2897</p> <p>Division Coordinator: Tommy Liskay <a href="mailto:Thomas.liskay@nationwidechildrens.org">Thomas.liskay@nationwidechildrens.org</a> PI: Dr. Nilsa Ramirez</p> <p><i>Mailing Address:</i> The Research Institute at Nationwide Children’s Hospital 700 Children’s Drive Rm WA1340 Columbus, OH 43205</p>	<p><b>Southern Division</b> Tel: 205-934-6071 Fax: 205-934-0816</p> <p>Division Coordinator: Kathy Sexton, <a href="mailto:sexton@uab.edu">sexton@uab.edu</a> PI: Dr. William Grizzle</p> <p><i>Mailing Address:</i> Tissue Procurement, ZRB 449 University of Alabama at Birmingham 1530 Third Ave. South Birmingham, AL 35294-0007</p>	<p><b>Western Division</b> Tel: 615-322-7486 Fax: 615-322-4741</p> <p>Division Coordinator: Kerry Wiles, <a href="mailto:kerry.wiles@vanderbilt.edu">kerry.wiles@vanderbilt.edu</a> PI: Dr. Kay Washington</p> <p><i>Mailing Address:</i> Vanderbilt University Medical Center 4918 TVC Building 22nd &amp; Pierce Ave. Nashville, TN 37232-5310</p>

**PRINCIPAL INVESTIGATOR INFORMATION**

First Name:                      Middle Name:                      Last Name:  
Salutation:                      Degree:                      Title:  
Institution Type:  Academic/Non-Profit     Government Lab     Commercial

**Mailing address:**

Institution:  
Department:  
Address 1:  
Address 2:  
City:                      State:                      Zip code:                      Country:  
Tel#:                      Alt. Tel#:                      Fax#:  
Email:

**LABORATORY CONTACT INFORMATION**

First Name:                      Middle Initial:                      Last Name:                      Title:  
Tel#:                      Alt. Tel#:                      Fax#:  
Email:

First Name:                      Middle Initial:                      Last Name:                      Title:  
Tel#:                      Alt. Tel#:                      Fax#:  
Email:

**SHIPPING INFORMATION**

Preferred Shipping Courier:                      Courier Account# (required):  
Shipping address same as mailing address:   
Attention:  
Institution:  
Department:  
Address 1:  
Address 2:  
City:                      State:                      Zip Code:                      Country:  
Tel#:                      Alt. Tel#:                      Fax#:  
Email:

## BILLING AND PAYMENT INFORMATION

### Billing contact:

First Name:                      Middle Initial:                      Last Name:                      Title:  
Tel#:                      Alt. Tel#:                      Fax#:  
Email:

### Billing address:

Same as mailing address:   
Attention:  
Institution:  
Address 1:  
Address 2:  
City:                      State:                      Zip code:                      Country:  
Tel#:                      Alt. Tel#:                      Fax#:  
Email:

**Payment details:**  Purchase Order (PO#)     Credit Card (Not accepted by all divisions, please contact the division coordinator.)

Purchase Order (PO)#:                      PO Expiration Date:                      PO Amount:  
Bill to Grant:                      Billing Ref#:  
Copy of Bill to Investigator:  Yes                       No  
Is PO intended for:  Use by any CHTN Division                       Use by only the primary CHTN Division

## PROJECT INFORMATION

### Project Title:

### IRB Review Type (IRB documentation required to show IRB review decision):

Full     Expedited     Exempt     Not Human Subjects Research  
 Human Use Agreement     Not required (TMA's only)

IRB#:                      IRB Expiration Date:                      Exempt-no expiration

### Funding Information:

Tissues will be provided to investigators on a rotating basis in the following priority order:

1. Peer reviewed funded investigators (including Federal and National laboratories).
2. New investigators and academic investigators developing new research projects.
3. Other investigators.

To help determine your priority, please include your major research grant. Institutional and other funding sources may also be listed.

**Funding Source #1:**

Grant#:

Grant Start Date:

Grant End Date:

Extramural peer-reviewed:  Yes  No

**Funding Source #2:**

Grant#:

Grant Start Date:

Grant End Date:

Extramural peer-reviewed:  Yes  No

Currently unfunded:

Please explain:

Please provide below a short research summary of the proposed research on the tissues you are requesting from the CHTN: (please click on the field to start typing)

## AGREEMENT FOR USE OF TISSUE

The recipient/investigator agrees that the tissues provided by the Cooperative Human Tissue Network (CHTN) will be used only for the purposes specified in this application. The recipient agrees not to attempt to obtain information identifying the individuals providing tissues to the CHTN. The recipient agrees that it shall not sell any portion of the tissues provided by the CHTN, or products directly extracted from these tissues (e.g. protein, mRNA or DNA). The recipient agrees that it shall not transfer tissue (or any portion thereof) supplied by the CHTN to third parties without the prior written permission of the CHTN.

The recipient understands that while the CHTN attempts to avoid providing tissues that are contaminated with highly infectious agents such as hepatitis and HIV, all tissues should be handled as if potentially infectious. The individuals who have supplied tissue to the CHTN have not agreed to have clinical tests performed on this tissue (e.g. for the presence of infective agents such as hepatitis), therefore, the recipient agrees not to perform such tests on the tissues supplied by the CHTN. The recipient acknowledges that the institution where the tissue will be used follows OSHA regulations for handling human specimens and will instruct their staff to abide by those rules. The recipient further agrees to assume all responsibility for informing and training personnel in the dangers and procedures for safe handling of human tissues.

Tissues are provided as a service to the research community without warranty of merchantability or fitness for a particular purpose or any other warranty, express or implied. The CHTN accepts no responsibility for any injury (including death) damages or loss that may arise either directly or indirectly from their use.

The recipient agrees to acknowledge the contributions of the Cooperative Human Tissue Network in all publications resulting from the use of these tissues. Recommended wording to the methods or acknowledgement section is as follows: *“Tissue samples were provided by the Cooperative Human Tissue Network which is funded by the National Cancer Institute. Other investigators may have received specimens from the same subjects.”*

**When tissue is to be used at State Institutions:** The institution agrees to be responsible for any claims, costs, damages, or expenses resulting from any injury (including death), damage or loss that may arise solely from the receipt, handling, storage and use of tissues received from the CHTN to the extent permitted under the laws of this State. The undersigned warrants that they have authority to execute this agreement on behalf of the recipient institution.

**When tissue is to be used at U.S. Government Agencies:** The US government assumes all risks and responsibilities in connection with the receipt, handling, storage and use of tissues received from the Cooperative Human Tissue Network. The United States assumes liability for any claims, damages, injury or expense arising from the use of the material or any derivative, but only to the extent provided under the Federal Tort Claims Act (28 U.S.C. Chap. 171).

**When tissue is to be used by all other institutions:** The institution agrees to assume all risks and responsibility in connection with the receipt, handling, storage and use of tissues from the Cooperative Human Tissue Network. It further agrees to indemnify and hold harmless the Cooperative Human Tissue Network and the United States Government from any claims costs, damages or expenses resulting from the use of the tissues provided by the CHTN. The undersigned warrant that they have authority to execute this agreement on behalf of the recipient institution.

### **BY MY SIGNATURE I AGREE TO THE TERMS SET FORTH IN THE ABOVE AGREEMENT**

Typed Name of PI Recipient \_\_\_\_\_ Agency \_\_\_\_\_

Typed Name of Official Authorized to Sign for the Agency \_\_\_\_\_

Signature of PI Recipient/Date \_\_\_\_\_ Division or Department \_\_\_\_\_

Authorized Signature of Agency Official/Date \_\_\_\_\_

**UPON RECEIPT OF THESE SIGNED UNDERSTANDINGS AND THE INFORMATION REQUESTED ABOVE, THE COOPERATIVE HUMAN TISSUE NETWORK WILL CONSIDER THIS REQUEST AND ALL FUTURE REQUESTS FOR TISSUE.** Specific questions about your application should be directed to your regional coordinator. Other questions may be directed to the NCI Program Director, Dr. Rodrigo Chuaqui at 301-496-7147.

**DATA USE AGREEMENT BETWEEN COOPERATIVE HUMAN TISSUE NETWORK (CHTN) INSTITUTIONS PROVIDING A LIMITED DATA SET AND LIMITED DATA SET RECIPIENTS**

This Data Use Agreement (“Agreement”) is designed to permit the use of a Limited Data Set for research pursuant to the Standards for Privacy of Individually Identifiable Health Information, (Privacy Rule) 45 CFR Parts 160 and 164. All terms used in this agreement are as defined in the Privacy Rule.

This Agreement is made and entered into as of this \_\_\_\_\_ day of \_\_\_\_\_, 20\_\_\_\_ by and between The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham, the University of Pennsylvania Health System and the University of Pennsylvania School of Medicine, The Rector and Visitors of the University of Virginia for the University of Virginia Medical Center, The Ohio State University, and The Research Institute at Nationwide Children’s Hospital, (“Covered Entities”), which operate as various divisions of the Cooperative Human Tissue Network (CHTN) and \_\_\_\_\_ (“Data Recipient”).

1. This Agreement sets forth the terms and conditions pursuant to which the Covered Entities will Disclose certain Protected Health Information (PHI) to the Data Recipient. PHI may include associated histopathologic, demographic, and clinical data that have been rendered a Limited Data set in compliance with 45 CFR 164.514(e) (1).
2. Except as otherwise specified herein, the Data Recipient may make Uses and Disclosures of the Limited Data Set consistent with the purpose of the research as described within their research application to the CHTN.
3. The individuals, or classes of individuals, who are permitted to Use or receive the Limited Data Set include the Data Recipient and other researchers or individuals directly involved with the research project described within their research application to the CHTN.
4. The Data Recipient agrees to not Use or Disclose the Limited Data Set for any purpose other than the Research Project or as Required by Law.
5. The Data Recipient agrees to use appropriate safeguards to prevent Use or Disclosure of the Limited Data Set other than as provided for by this Agreement.
6. The Data Recipient agrees to report to the Covered Entities any Use or Disclosure of the Limited Data Set not provided for by this Agreement, of which it becomes aware, including without limitation, any Disclosure of PHI to an unauthorized subcontractor.
7. The Data Recipient agrees to ensure that any agent, including a subcontractor, to whom it provides the Limited Data Set, agrees to the same restrictions and conditions that apply through this Agreement to the Data Recipient with respect to such information.
8. The Data Recipient agrees not to attempt to identify or contact the individual(s) to whom the Limited Data Set applies.
9. This agreement may be terminated by the Covered Entities upon five (5) days written notice to the Data Recipient if the Data Recipient materially breaches any provision contained in this Agreement and such breach is not cured within the five (5) day period. The Data Recipient acknowledges that if efforts to cure the breach are unsuccessful, the Covered Entities may discontinue disclosure of Protected Health Information and report the problem to the Secretary of the Department of Health and Human Services.
10. The terms of this agreement can be changed only by written modification signed by both parties.

**DATA RECIPIENT**

Name of Principal Investigator \_\_\_\_\_ Title \_\_\_\_\_

Authorized Signature \_\_\_\_\_ Date \_\_\_\_\_

## REQUEST INFORMATION FORM

**If requesting specimens from more than one specific anatomic site or disease, please complete separate copies of this form, the Request Donor Details form and the accompanying Preparation Details form.** Please be specific about your requirements, including those for storing and handling tissue samples from the time the specimens are collected until they are delivered to your lab (i.e. transport media, refrigeration status, etc.).

REQUEST INFORMATION: BIOSPECIMEN TYPE	
Please check the appropriate tissue type below, and complete the details for the biospecimen type requested. <b>(If submitting more than one request, complete a separate copy of this form for EACH request.)</b>	
<input type="checkbox"/> Malignant Neoplasm <input type="checkbox"/> Normal Biospecimen <input type="checkbox"/> Any Biospecimen	<input type="checkbox"/> Benign Neoplasm <input type="checkbox"/> Non-Neoplastic Disease
Primary Organ Site:	Diagnosis Type(s):
Total number of donors requested:	
If requesting <b>MALIGNANT</b> , <b>BENIGN</b> neoplasm, or <b>DISEASED</b> <u>solid tissue</u> please check all that apply:	
<input type="checkbox"/> Primary Tumor ( <i>if malignant</i> ) or Diseased Tissue	<input type="checkbox"/> Required or <input type="checkbox"/> If available
<input type="checkbox"/> Metastatic Tumor ( <i>applicable for malignant requests only</i> )	<input type="checkbox"/> Required or <input type="checkbox"/> If available
<input type="checkbox"/> Matching Grossly Uninvolved Tissue	<input type="checkbox"/> Required or <input type="checkbox"/> If available
<input type="checkbox"/> Matching Tissue Other Site (Site:        )	<input type="checkbox"/> Required or <input type="checkbox"/> If available
If requesting <b>FLUID</b> biospecimens:	
<input type="checkbox"/> Body Fluid (Type:        )	<input type="checkbox"/> Required or <input type="checkbox"/> If available
If requesting <b>NORMAL</b> biospecimen, please check all that apply:	
Normal from healthy donors with no significant medical condition is acceptable:	<input type="checkbox"/> Yes <input type="checkbox"/> No
Normal or grossly uninvolved from donors with non-neoplastic disease is acceptable:	<input type="checkbox"/> Yes <input type="checkbox"/> No
Normal or grossly uninvolved from donors with cancer or a history of cancer is acceptable:	<input type="checkbox"/> Yes <input type="checkbox"/> No

## REQUEST INFORMATION: DONOR DETAILS

### Donor Demographics:

Gender:  Male  Female  Any Race:

Age Range 1: Minimum: Maximum:

Age Range 2: Minimum: Maximum:

### Donor History:

Standard Information provided at no additional cost includes age, gender, race, and the final pathology diagnosis (typically a copy of the final pathology report) or CHTN QA assessment where applicable. Any requests for additional information, including prior therapy questions below, require prior CHTN approval and may incur an additional fee for chart review. Availability and completeness of clinical information is not guaranteed.

Additional Chart Review Required:  Yes  No

Review Information Requested:

Accept tissue from patients who have had prior chemotherapy:

Yes  No  Unknown treatment status is acceptable

If YES, please check the following options:

- Yes for different disease
- Yes for prior presentation of this disease
- Yes with neoadjuvant treatment for this procedure

Accept tissue from patients who have had prior radiation therapy:

Yes  No  Unknown Treatment status is acceptable

If YES, please check the following options:

- Yes for different disease
- Yes for prior presentation of this disease
- Yes with neoadjuvant treatment for this procedure

### Procedure Type (check all that apply):

- |   |  |
|---|--|
| <input type="checkbox"/> Surgery – Post Excision Time:      | <input type="checkbox"/> Time Not Applicable |
| <input type="checkbox"/> Autopsy – Post Mortem Time:        | <input type="checkbox"/> Time Not Applicable |
| <input type="checkbox"/> Transplant – Post Transplant Time: | <input type="checkbox"/> Time Not Applicable |
| <input type="checkbox"/> Phlebotomy – Post Phlebotomy Time: | <input type="checkbox"/> Time Not Applicable |

Please indicate the order of priority (1 being the highest priority) of the preparation type if you are requesting more than one preparation type for the same tissue specimen.

## REQUEST INFORMATION: PREPARATION DETAILS

### FRESH PREP TYPE

Required  If available Preparation priority (See above note):

**Standard Fresh Preps:**  RPMI  DMEM  Dry  PBS  Saline  RNALater  
 Slides-Touch preps (#req'd )  Other

Investigator Supplied Media (Name of Media: ) **MSDS SHEET IS REQUIRED**

Additional Media Supplements (type and concentration)

Antibiotics (100 µg/mL Penicillin and 100 µg/mL Streptomycin)  Fetal Bovine Serum 10%

Antimycotic Fungizone (2.5 µg/mL Amphotericin B)

Note: If other additives are requested, please contact your divisional coordinator.

**Biospecimen size:** Minimum Weight: Maximum Weight:

Minimum Dimensions: L H W

Minimum Volume (fluids):  mL  µL

### FROZEN PREP TYPE

Required  If available Preparation priority (See above note):

**Standard Freezing Methods:**  LN2 vapor phase  Immersed in LN2 liquid  OCT

**Non-standard Freezing Methods:**  Frz -20  Frz -80  Frz in isopentane  Dry Ice  
 Scroll/Ribbon  Macrodissection  Other

**Slides:**  H&E slides (#req'd )  Frozen sections (#req'd )

Touch prep slides (#req'd )

**Biospecimen size:** Minimum Weight: Maximum Weight:

Minimum Dimensions: L H W

Minimum Volume (fluids):  mL  µL

### FIXED PREP TYPE

Required  If available Preparation priority (See above note):

**Fixation Methods:**  Paraffin Block (Formalin 10%)  Floating in Formalin  Scroll/Ribbon

**Slides:**  H&E slides (#req'd )  Unstained slides (#req'd )

Touch prep slides (#req'd )  Other

**Biospecimen size:** Minimum Weight: Maximum Weight:

Minimum Dimensions: L H W

### SHIPPING

Target # of Specimens in a shipment:

Saturday delivery:  Yes  No  If notified

Shipping Instructions: Frozen:  Dry ice  Ice pack  
Refrigerated:  Wet ice  Cold pack  
Non-refrigerated:  Ambient temperature

Shipping Choices:  Ship day of procurement to arrive next day (standard for fresh shipments)  
 Standard overnight shipment  Investigator pickup same day as procured

## TISSUE MICROARRAY REQUEST INFORMATION FORM

**Current TMA designs are listed below. You may request up to a maximum 10 slides per array design, subject to CHTN approval and availability.** Slides provided will be serial sections from the same TMA block. All replicate blocks of a particular design utilize cores from the same set of donors. Unstained histologic sections are 4 microns thick, on charged glass slides. Please see the CHTN website, <http://avillage.web.virginia.edu/CHTN>, for additional details.

### TISSUE MICROARRAY SLIDES

Please check the desired TMAs below and indicate the number of slides requested per design.

**Test TMA** # of slides requested:

TMA series CHTN Test contain 6 human tissue types (colonic mucosa, prostate, breast carcinoma, spleen, liver and uterine smooth muscle) in 0.6 mm spot sizes. These are useful for determining assay conditions and procedures before using more expensive comprehensive TMA slides.

**Normal Biospecimen TMA** # of slides requested:

The normal tissue CHTN\_NORM2 TMA contains 50 human tissue types in 1.0 mm spot sizes. Most samples are of normal, non-neoplastic adult tissue obtained from surgical resection specimens, excepting parathyroid from a hyperplastic parathyroid gland and central nervous system tissue (cerebral cortex and white matter) from autopsy. This TMA is designed provide researchers with a screening tool containing most of the cell types present in the human body.

**Human Central Nervous System TMA** # of slides requested:

The CHTN CNS1 TMA samples 12 areas of the central nervous system and supporting structures, capturing most of the major cell types of the brain and spinal cord. Each target tissue type is sampled three times with 1.5 mm cores. This TMA is meant to provide an initial survey tool for determining gene expression patterns in different cell types of the central nervous system.

**Normal Endometrial Menstrual Cycle TMA** # of slides requested:

The CHTNEndoN1 TMA samples normally functioning endometrium through the endometrial cycle. There are 10 cases each of proliferative-phase endometrium, 10 cases each of secretory endometrium at post-ovulatory days 16-18, 19-20, 21-22, 23-24, 25-26 and 7 cases each of secretory endometrium at post-ovulatory days 27-28. Each target tissue type is sampled twice with 1.0 mm cores. This TMA is meant to provide an initial survey tool for determining gene expression patterns in endometrial tissue during the menstrual cycle.

**Colorectal Carcinoma Progression TMA** # of slides requested:

The CHTN\_CRC2 TMA contains up to 20 cases of non-neoplastic colonic mucosa, 14 cases of adenomatous polyps, 14 cases of primary colorectal adenocarcinomas, 7 cases of adenocarcinoma metastatic to regional lymph nodes and 7 cases of adenocarcinoma metastatic to distant organs. Each case is sampled three times with 0.6 mm cores. This TMA represents a limited number of cases that may detect strong trends in differential gene expression and is intended for pilot surveys and generation of hypotheses. This TMA does not contain case numbers of sufficient quantity to prove the clinical utility of a marker.

**Ovarian Carcinoma Survey TMA** # of slides requested:

The CHTN OvCa1 TMA contains examples of the major histologic types of epithelial ovarian cancer. Each case is sampled four times with 0.6 mm cores. The TMA design includes 20 cases each of serous papillary carcinoma (well to moderately differentiated), clear cell carcinoma, endometrioid adenocarcinoma and mucinous adenocarcinoma). Another 20 cases of poorly and undifferentiated carcinoma are also provided. This TMA may detect strong trends in differential gene expression among the different histologic types of ovarian carcinoma, and is intended for pilot surveys and generation of hypotheses. This TMA is not designed to prove the clinical utility of prognostic biomarkers.

**Other TMA** # of slides requested:

For additional information on TMA slides, please contact the Mid-Atlantic Division at (434) 924-9879 or email your query to Craig Rumpel ([crumpel@virginia.edu](mailto:crumpel@virginia.edu)).